ACRV Earnings — Acrivon Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
ACRV — Acrivon Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.60
Market Cap$68.5M
P/E—
52W Range$1.05 – $3.56
Next Earnings2026-08-12
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
